Severe Bullous Drug Eruption and Filgrastim

Rare Diseases Clinical Trial

— GNET  

Official title:

Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04651439
• Other study ID #: 69HCL19_0375
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: May 13, 2022
• Est. completion date: May 13, 2026

Study information

• Verified date: May 2023
• Source: Hospices Civils de Lyon
• Contact: Benoit BEN SAID, MD
• Phone: 472 117 211
• Email: benoit.ben-said[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Toxic epidermal necrolysis (TEN) including Stevens Johnson (SJS) and Lyell syndromes represent the most severe drug eruptions. It is an allergic disorder caused by cytotoxic T lymphocytes, specific of drugs, responsible for the destruction of keratinocytes by apoptosis. Regulatory T cell (CD25 high CD4+), normally responsible for controlling the activation of cytotoxic T lymphocytes, have altered function. Despite the progress made in the pathophysiological understanding of TEN, there is currently no effective treatment. The main symptom is bullous and skin peeling > 10% giving the appearance of great burns. The death rate is estimated between 30 and 40% due to visceral inflammatory injuries and bacterial superinfection. The risk of mortality is estimated during the initial treatment by calculating the SCORTEN (mortality>10% if SCORTEN>2, mortality>90% if SCORTEN>5). The morbidity is also very important (92% at 1 year), especially ophthalmologic with high risk of blindness... The therapeutic potential of G-CSF (Granulocyte-Colony Stimulating Factor) in TEN is supported by several observations. The G-CSF promotes skin healing. This has been shown in human burns, with a significant reduction in healing time under G-CSF. The mechanisms associate the growth factor effect on keratinocytes, macrophages stimulation and metalloprotease activity allowing tissue remodeling limiting sequels onset. Otherwise, healing altered in deficient G-CSF mice is corrected by the growth factor injection. The G-CSF is an immunomodulator whose activities appear to justify use in TEN : - Polarization of immune response to Th2 non-cytotoxic (anti Th1), - Preferential differentiation of naive LT (T lymphocytes) in regulator LT (CD25 high CD4+) and mobilization of regulator LT of the spinal cord to altered tissues. The G-CSF was used in a few cases of TEN with great efficacy. No data is available concerning sequels of SJS/TEN in treated patients. This clinical trial program, by providing proof of the efficacy of filgrastim in SJS/TEN, should allow progress in care of this serious toxics diseases. In the future, it could thus reduce the significant morbidity of these syndromes with a high rate of sequelae.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 42
• Est. completion date: May 13, 2026
• Est. primary completion date: May 18, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

• Patient aged of 6 years old or more, presenting SJS/TEN, drug or infectious origin proofed and very strongly suspected (indirect certainty argument), confirmed by evaluator.
• SJS or TEN evolving since less than 7 days with a progression of the detachment or the eruption observed dating less than 48 hours.
• Patient and/or have right able to understand the objectives of the trial and having given their written consent to participate (parents for minors, have right for patients in immediate life-saving emergency).
• Patient registered with a social security scheme or benefiting from a similar scheme.
• Pregnancy test beta HCG negative for women of childbearing age

Exclusion Criteria:

• Patient weighing less than 20kg
• Chronic myeloid pathology such as myeloid leukemia or AML (acute myeloid leukemia)
• Thrombophilia or thrombotic pathology in progress
• PNN (polymorphonuclear neutrophils) > 50.000 on the CBC (Complete Blood Count) during the inclusion visit
• Patient who received cyclosporine, anti-TNFalpha or intravenous immunoglobulins or lithium in the month prior the inclusion
• Pregnant or breastfeeding woman
• Patient under protective measure (safeguard measure, curatorship, guardianship) or deprived of liberty
• Patient in exclusion period after participation at other interventional clinical trial
• Known hypersensitivity to the active substance (FILGRASTIM) or to the one of the excipients (glutamine acid, sorbitol E420, Polysorbate 80)
• Patient presenting a known glucose intolerance or hereditary fructose intolerance
• Patient with a traumatic brain injury less than 24 hours
• Patient admitted with septic shock

Related Conditions & MeSH terms

• Rare Diseases
• Stevens-Johnson Syndrome
• Toxic Epidermal Necrolyses

Intervention

Drug:
• Filgrastim
Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight : 20 to < 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route) 30 to < 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV) 60 to < 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV) 90 to < 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV) 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV) > 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)
• Placebo
Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim : 20 to < 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected. 30 to < 60kg = 20mL of Glucose 5% solution (by IV) 60 to < 90kg = 20mL of Glucose 5% solution (by IV) 90 to < 120kg = 20mL of Glucose 5% solution (by IV) 120 to 150kg = 20mL of Glucose 5% solution (by IV) > 150kg = 20mL of Glucose 5% solution (by IV)

Locations

Country	Name	City	State
France	Reference center for toxic bullous dermatoses and severe drug eruptions, Edouard Herriot Hospital, Hospices Civils de Lyon	Lyon
France	Service de Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon	Lyon
France	Département d'Anesthésie-Réanimation , Hôpital Edouard Herriot, Hospices Civils de Lyon	LYON cedex 03

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Arrest of the SJS/NET progression at day 5	Comparison between the 2 arms of the proportion of patients with arrest of progression of skin detachment defined by a peeled surface and/or bullous and/or associated at a NIKOLSKY sign determined according to the stable burn table - Evaluation done by the Outcomes Assessor and the adjudication committee.	On day 5 (after 5 injections of ZARZIO or PLACEBO - D0: initiation of treatment)
Secondary	Arrest of the SJS/NET progression	Comparison between the 2 arms of the time until the arrest of the SJS/NET progression defined by a peeled surface and/or bullous and/or associated at a NIKOLSKY sign determined according to the stable burn table - Evaluation done by the Outcomes Assessor and the adjudication committee.	At day 3, day 7 and day 15
Secondary	Complete re-epidermization	Comparison between the 2 arms of the time until the complete re-epidermization defined by the disappearance of skin rashes and return to normal skin. Evaluation done by the Outcomes Assessor and the adjudication committee.	At day 3, day 5, day 7, day 15 and day 45
Secondary	Overall survival	Comparison between the 2 arms of the overall survival	Until 30 days
Secondary	Overall survival	Comparison between the 2 arms of the overall survival	Until 1 year
Secondary	Duration of hospitalization	Comparison between the 2 arms of the number days of hospitalization corresponding to the duration of SJS/NET episode's hospitalization.	15 days (maximal of SJS/NET episode's hospitalization)
Secondary	Premature discontinuation of experimental treatment	Number of clinical and biological adverse event leading to stop the filgrastim treatment (per patient, nature and grade of the AE (adverse event ) - repository CTCAE version 5.0)	Between day 0 and day 5
Secondary	Adverse events	Comparison between the 2 arms of the number of clinical and biological adverse event (by organ systems - repository CTCAE version 5.0)..	Until 1 year
Secondary	Use of systemic corticosteroid therapy	Study of the nature, cumulative doses and indications objectifying a corticosteroid prescription. A comparison between the 2 arms will be done.	Between day 0 and day 15
Secondary	Evaluation of sequels	Determination of the proportion of patients with at least one sequel among the following specialty : ophthalmology, stomatology/ORL(otorhinolaryngology), gastroenterology, gynecology, urology and psychiatry, researched during specialized consultations during the remote monitoring phase. A comparison between the 2 arms will be done.	At day 45, day 60, day 90, day 180 and 1 year
Secondary	Quality of life evolution	Quality of life evolution assessed with Dermatology Life Quality Index (DLQI) or Children's Dermatology Life Quality Index (CDLQI).; DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.; CDLQI is used in the same way. It is documented in 5 minutes. Each question is illustrated by a cartoon based on the theme of the question, making it more fun for younger children. The scoring for each question is "Very much"[Score = 3], "Quite a lot"[2], "Only a little"[1], "Not at all"[0], "Blank"[0], and Q7 - "prevented school"[3]. The 10 individual question scores are summed to provide a total CDLQI score. The maximum possible score is 30, indicating maximum impact on QoL.; A comparison between the 2 arms will be done.	At day 60, day 180 and 1 year
Secondary	Risk of developing Post Traumatic Stress Disorder (PTSD)	Determination of the proportion of patients with high risk of developing PTSD measured with Impact of Event Scale Revised (IES-R) or Children's Revised Impact of Event Scale (CRIES).; IES-R is a 22-item self-administered questionnaire that measures symptoms of intrusion, avoidance and over-arousal experienced during the past 7 days. Patients rate each item on a 0-5 point Likert scale. The total score, between 0 and 88, is obtained by adding all the ratings for each item: low risk (score less than 12), moderate (score between 12 and 34 inclusive) or at high risk (score strictly greater than 34) of developing PTSD.; CRIES-13 is a revised scale to measure the impact of events on children from 8 years old. Items are rated on a 4-point scale, with scores of 0, 1, 3 and 5 points. The maximum score is 65. The score is obtained by adding the responses to each item. A score of 30 or more would be effective in screening for PTSD.; A comparison between the 2 arms will be done.	At day 0, day 7 and day 15